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ABSTRACT
Purpose: 12b80 combines doxorubicin bound to a bone targeting 
hydroxybisphosphonate vector using a pH-sensitive linker, designed to specifically 
trigger doxorubicin release in an acidic bone tumor microenvironment. This phase 
I study aimed to determine the safety and toxicity profiles of 12b80 in dogs with 
naturally occurring osteosarcoma, with the objective to translate findings from dogs 
to humans.
Experimental Design: Ten client-owned dogs with osteosarcoma were enrolled 
in an accelerated dose-titration design followed by 3 + 3 design. Dogs received three 
cycles of 12b80 intravenous injection at 4 mg/kg (n = 1), 6 mg/kg (n = 2), 8 mg/
kg (n = 3), and 10 mg/kg (n = 4). Endpoints included safety, tolerability, maximum 
tolerated dose (MTD), and dose-limiting toxicity (DLT).
Results: The MTD of 12b80 was 8 mg/kg (i.e., equivalent dose of doxorubicin of 
110 mg/m2, range: 93–126). Most adverse events included grade ≤ 2 gastrointestinal 
disorders and hypersensitivity reactions. No hematological or cardiac DLT were 
observed at any dose tested.
Conclusions: In dogs, 12b80 is overall well tolerated and expends the MTD of 
doxorubicin up to four times the standard dose of 30 mg/m2. These results demonstrate 
the potential therapeutic benefit of 12b80 in canine and human osteosarcoma.
INTRODUCTION
Research in comparative oncology has demonstrated 
that naturally occurring canine cancers are of valuable 
and translatable interest for the understanding of human 
cancer biology and characterization of new therapies 
[1–4]. Osteosarcoma is the most common primary bone 
tumor reported in both human and companion dog 
populations [5, 6]. Canine osteosarcoma is a suitable 
model for human osteosarcoma due to their similar 
clinical presentation, molecular features and therapeutic 
responses, offering a unique opportunity for preclinical 
modelling to allow development of innovative therapies 
for human patients [7–11]. In dogs, the prognosis 
remains poor. The median disease-free interval in dogs 
with appendicular osteosarcoma following surgery and 
adjuvant chemotherapy ranges from 135 to 425 days with 
a median overall survival ranging from 258 to 479 days 
[12–19]. Therefore, identifying novel strategies targeting 
cancer cells and more effective treatments are urgently 
needed to improve survival in both humans and dogs with 
osteosarcoma.
The most commonly studied adjuvant chemotherapy 
drugs used in dogs are cisplatin, carboplatin and 
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doxorubicin, administered either as single agents or in 
concurrent or alternating combinations [12–19]. Despite 
the numerous chemotherapy protocols described for 
canine osteosarcoma, there is currently no consensus on 
the optimal chemotherapy protocol in dogs. For non-
operable or metastatic disease, palliative treatments 
include radiation therapy, chemotherapy, bisphosphonate 
or oral analgesics, providing short-term pain control 
ranging from a median of 53 to 202 days [20–24].
Osteosarcoma originates from osteoblasts and 
promotes tumor osteoid production and tumoral 
heterotopic bone tissue formation. In addition, 
concomitant activation of osteoclasts by tumor cells leads 
to osteolysis and an acidic tumor microenvironment. 
The molecule 12b80 is a new antineoplastic compound, 
combining doxorubicin bound to a bone targeting 
hydroxybisphosphonate (HBP) vector using a pH-sensitive 
linker [25]. This HBP linked doxorubicin compound was 
designed to specifically trigger doxorubicin release in 
an acidic bone tumor microenvironment, promoting the 
selective uptake of the drug by tumor cells and in turn, 
decreasing systemic distribution and associated toxicity. 
In in vitro study, 12b80 displays a rapid and sustained 
targeting of bone tissue [25]. In in vivo study, 12b80 
allows higher doxorubicin concentration in the tumor bone 
environment compared to nonvectorized doxorubicin, 
exhibits strong antitumor effects on rodent orthotopic 
osteosarcoma, and demonstrates a dose-response 
therapeutic activity more potent than doxorubicin/
zoledronate combination [25].
Based on these preclinical data, the following 
study was designed to evaluate the safety and tolerability, 
maximum tolerated dose (MTD) and dose-limiting 
toxicity (DLT) of 12b80 in companion dogs with naturally 
occurring osteosarcoma. Preliminary antitumor efficacy 
of 12b80 was also evaluated. This dose escalation study 
represents a pilot translational research study for future 
phase II randomized double-blind trial of 12b80 in 
naturally occurring osteosarcoma in dogs. In this capacity, 
companion dogs can serve as valuable corroborative 
models for assessing the efficacy of novel therapies, some 
of which could potentially be of therapeutic value in 
human osteosarcoma.
RESULTS
Clinical characteristics and drug dosing
Ten client-owned dogs were enrolled in the clinical 
trial between September 23, 2015 and October 13, 2016. 
The last day of follow-up was May 19, 2018. Baseline 
characteristics are summarized in Table 1.
All ten dogs had biopsy-confirmed diagnosis of 
osteosarcoma. Nine (90%) dogs were diagnosed with an 
osteoblastic osteosarcoma and one (10%) dog diagnosed 
with a fibroblastic osteosarcoma. Tumor locations 
included proximal humerus (n = 4), distal radius (n = 2), 
distal ulna (n = 2), distal tibia (n = 1) and proximal tibia 
(n = 1). At the time of enrollment, macroscopic metastatic 
disease was identified in four (40%) dogs. Three dogs 
presented with pulmonary metastatic disease, and one dog 
with pulmonary and vertebral metastatic disease based on 
contrast-enhanced computed tomography.
All dogs involved in the trial followed the same 
protocol over a period of nine weeks, consisting of three 
cycles of 12b80 intravenous (IV) injections, administered 
every three weeks (day 1, day 22, day 43). The dose of 
12b80 was escalated from 4 mg/kg to 10 mg/kg (Table 2). 
Dogs started 12b80 treatment at a dose of 4 mg/kg (n 
= 1) and 6 mg/kg (n = 2), divided in two intravenous 
administrations of a 1-hour constant rate infusion over 24 
hours. No DLT was observed and additional dogs were 
enrolled to determine the MTD in a 3 + 3 dose escalation 
design. Three dogs were treated at a dose of 8 mg/kg and 
four dogs at a dose of 10 mg/kg. One dog, initially treated 
with three cycles at 6 mg/kg, had undergone an intra-patient 
dose escalation to receive 8 mg/kg. In total four dogs were 
treated at 8 mg/kg. Four dogs developed grade 1 immediate 
hypersensitivity reactions (IHR) during drug administration 
including facial pruritus, head shaking, or facial edema: two 
of these dogs were treated with 12b80 at 8 mg/kg and two 
dogs were treated at 10 mg/kg. All signs of IHR resolved 
after a reduction in the rate of the infusion. Therefore, at 
doses of 8 mg/kg and 10 mg/kg, the administration schedule 
was changed from two to three (n = 3) or four (n = 2) 
intravenous infusions of 1-hour of each over 48 hours.
Six (60%) dogs completed the three cycles protocol, 
including two (2/2, 100%) dogs treated with 6 mg/kg, one 
(1/3, 33%) dog treated with 8 mg/kg and three (3/4, 75%) 
dogs treated with 10 mg/kg. Based on the weight of dogs 
included in each cohort, a 12b80 dose of 4 mg/kg, 6 mg/
kg, 8 mg/kg and 10 mg/kg represents, in average, the 
equivalent calculated dose of doxorubicin of 48 mg/m2, 
78 mg/m2, 110 mg/m2, and 141.8 mg/m2 respectively. The 
range of the equivalent cumulative dose of doxorubicin 
administered for each cohort treated with 12b80 is 
shown in Table 2. The dog that had an intra-patient dose 
escalation of 12b80 completed the three cycles at 6 mg/
kg and received three additional cycles at 8 mg/kg. This 
dog received a 12b80 cumulative dose of 42 mg/kg and an 
equivalent cumulative dose of doxorubicin of 528 mg/m2.
Safety
All ten dogs were evaluable for safety analysis 
and DLT analysis. Twenty-eight cycles of 12b80 were 
evaluated and the type, frequency and severity of 
treatment-emergent adverse events (TEAE) were graded 
according to the Veterinary Cooperative Oncology 
Group criteria for adverse events (VCOG-CTCAE), 
version 1.1 [26]. Thirty-one TEAE were reported in 
eight (80%) dogs (Table 3). The most frequently reported 
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TEAE included IHR (6/31, 19%), vomiting (6/31, 19%), 
thrombocytopenia (5/31, 16%), diarrhea (3/31, 10%), 
anemia (3/31, 10%), neutropenia (2/31, 6%), decreased 
appetite (2/31, 6%), elevated alanine transaminase (1/31, 
3%) and urea (1/31, 3%). The majority (29/31, 94%) of the 
TEAE were grade 1 or 2. All hypersensitivity reactions, 
neutropenia and anemia episodes were grade 1. Three 
thrombocytopenic episodes were grade 1 and two were 
grade 2. Full hematological recovery was confirmed 
before initiation of the next 12b80 cycle in all dogs. No 
grade ≥ 3 hematological or biochemical toxicity were 
reported.
Two severe TEAE were observed in two dogs 
treated with 10 mg/kg and were considered as DLT. One 
dog developed one grade 3 phlebitis and necrosis at the 
IV injection site, which required a surgical intervention. 
This dog had received the 12b80 IV through an indwelling 
catheter and this event occurred 7 days after the last 
administration. One dog developed one grade 5 septic 
shock with septic peritonitis secondary to duodenal 
perforation. This dog had received concomitant long-term 
nonsteroidal anti-inflammatory drugs (NSAID) and this 
event occurred 14 days after the last dose of 12b80.
No DLT occurred at dose of 4 mg/kg, 6 mg/kg and 
8 mg/kg and two dogs developed DLT at dose 10 mg/
kg. The MTD and the recommended phase I dose were 
therefore determined at 8 mg/kg.
Circulating blood cell counts in dogs treated with 
12b80
The circulating blood cell counts including 
neutrophils, platelets and red blood cells before and seven 
days after each cycle of 12b80 are shown in Figure 1. 
Table 1: Baseline characteristics of dogs treated with 12b80 (n = 10)
Baseline characteristics Dogs treated with 12b80
Age, years, mean ± SD (range) 8.3 ± 2.2 (5.6–12.5)
Body weight, kg, mean ± SD (range) 44.8 ± 16 (27.7–70.0)
Sex, no. (%)
Male 4 (40%)
Female 6 (60%)
Breed, no.
Rottweiler 2
Dogue de Bordeaux 1
German Shepherd 1
Golden Retriever 1
Great Dane 1
Great Pyrenees 1
Saint Bernard 1
Cross Breed 2
Tumor location, no. (%)
Proximal humerus 4 (40%)
Distal radius 2 (20%)
Distal ulna 2 (20%)
Distal tibia 1 (10%)
Proximal tibia 1 (10%)
Histopathological subtype, no. (%)
Osteoblastic 9 (90%)
Fibroblastic 1 (10%)
Pretreatment alkaline phosphatase activity (ALP), no. (%)
Normal 6 (60%)
Elevated 4 (40%)
Metastatic disease at the time of enrollment, no. (%)
Absent 6 (60%)
Present 4 (40%)
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There was no dose-effect relationship between the dose of 
12b80 and the number of neutrophils observed. There was 
no statistically significant decrease in neutrophil count 
seven days post treatment. Transient decrease in platelet 
count occurred 7 days post 12b80 administration. No 
hematological DLT were observed at any dose tested.
Cardiac evaluation
Six (60%) dogs completed the protocol 
consistent of three cycles of 12b80 and had a follow-up 
echocardiography performed at day 57. No significant 
sustained changes in cardiac parameters or cardiac 
function were identified in any dog. Among these six dogs, 
three (3/6, 50%) had post-mortem cardiac histopathology 
performed (Figure 2A–2C). Those dogs received a 12b80 
cumulative dose of 20 mg/kg, 30 mg/kg and 42 mg/kg 
respectively. The first dog received two cycles at 10 mg/
kg, the second dog received three cycles at 10 mg/kg and 
the latter dog was treated with three cycles of 12b80 at 6 
mg/kg and three additional cycles at 8 mg/kg. No severe 
macroscopic or histopathological lesions were observed. A 
diffuse increase in cardiomyocytes density was reported in 
the dog treated at 20 mg/kg cumulative dose (Figure 2A) 
and rare individual cell necrosis was noted in the dog 
treated at 42 mg/kg cumulative dose (Figure 2C). These 
histopathological changes were not accompanied by 
deteriorating cardiac function.
Efficacy endpoints
Six (60%) dogs completed the three cycles of 12b80 
and had a follow-up computed tomography performed 
at day 57. The response to treatment was evaluated 
according to the Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.0 [27]. Four dogs did not 
have repeat imaging because of euthanasia for poor quality 
of life (n = 1), grade 5 septic shock (n = 1), and exclusion 
from the trial due to a pathological fracture (n = 2). Stable 
disease was reported in two (2/6, 33%) dogs (Figure 2J–
Table 2: Dose escalation design of 12b80 evaluated in ten client-owned dogs with naturally occurring 
osteosarcoma
Cohort
(Number of dogs)
Dose of 12b80/
Cycle
Number of cycle 
administered / dog 
Mean (range)
Cumulative dose of 
12b80 administered 
Mean (range)
Equivalent dose of 
doxorubicin / Cycle 
Mean (range)
Equivalent cumulative dose 
of doxorubicin administered 
Mean (range)
Cohort 1 (n = 1) 4 mg/kg n = 1 4 mg/kg 48 mg/m2 48 mg/m2
Cohort 2 (n = 2) 6 mg/kg n = 3 18 mg/kg 78 mg/m2 (75–81) 234 mg/m2 (225–243)
Cohort 3 (n = 3) 8 mg/kg n = 2.33 (2–3) 18.7 mg/kg 110 mg/m2 (93–126) 257 mg/m2 (186–333)
Cohort 4 (n = 4) 10 mg/kg n = 2.75 (2–3) 27.5 mg/kg (20–30) 141.8 mg/m2 (120–159) 391.5 mg/m2 (270–477)
Four doses were evaluated in an accelerated dose-titration design followed by a 3 + 3 design. The dose of 12b80 was escalated 
from 4 mg/kg to 10 mg/kg. The equivalent calculated dose of doxorubicin administered is shown.
Table 3: Hematological and non-hematological adverse events graded according to the Veterinary 
Cooperative Oncology Group criteria for adverse events (VCOG-CTCAE), version 1.1
TEAE 4 mg/kg 6 mg/kg 8 mg/kg 10 mg/kg Overall
Hematological adverse events, grade (number of TEAE)
Anemia Grade 1 (1) Grade 1 (1) — Grade 1 (1) Grade 1 (3)
Neutropenia — — Grade 1 (1) Grade 1 (1) Grade 1 (2)
Thrombocytopenia — Grade 2 (1) Grade 1 (1) Grade 1 (2) Grade 1 (3)
Grade 2 (1) Grade 2 (2)
Non-hematological adverse events, grade (number of TEAE)
Vomiting Grade 1 (1) — Grade 1 (1) Grade 1 (2) Grade 1 (4)
Grade 2 (2) Grade 2 (2)
Diarrhea — — Grade 1 (1) Grade 1 (1) Grade 1 (2)
Grade 2 (1) Grade 2 (1)
Hypersensitivity reaction — — Grade 1 (2) Grade 1 (4) Grade 1 (6)
Decreased appetite — — Grade 1 (1) Grade 1 (1) Grade 1 (2)
ALT elevation — — Grade 2 (1) — Grade 2 (1)
Urea elevation — — Grade 2 (1) — Grade 2 (1)
Phlebitis and necrosis at the IV injection site — — — Grade 3 (1) Grade 3 (1)
Septic shock — — — Grade 5 (1) Grade 5 (1)
ALT: alanine transaminase; IV: intravenous; TEAE: treatment-emergent adverse events.
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2M). One dog was treated with three cycles of 12b80 at 8 
mg/kg and one dog was treated with three cycles of 12b80 
at 10 mg/kg. The latter dog presented a persistent stable 
disease on follow-up computed tomography at four- and 
six-months post treatment. Four dogs had progressive 
disease in both primary and metastatic sites at day 57. 
Subjective pain control was reported by owners in four 
out of six (67%) dogs after the completion of three cycles 
of 12b80. The median survival time for all dogs was 57 
days (range: 16–766). The median survival time for dogs 
that completed the three cycles of 12b80 was 157 days 
(range: 56–766). The cause of euthanasia was related to 
poor quality of life in five dogs, pathological fracture in 
four dogs, and septic shock in one dog.
Post treatment bone tumor histopathology and 
necropsy examination
Tumor biopsies were repeated in five (50%) dogs 
at D57. Histopathology analysis of post treatment bone 
tumor biopsies revealed a stable mitotic index in two 
dogs: one dog treated at 8 mg/kg and one dog treated at 
10 mg/kg. In addition, post treatment bone tumor biopsies 
were performed in nine (90%) dogs following euthanasia. 
An increased necrosis was noted in five dogs on post-
mortem histopathology compared with the pretreatment 
histopathology analysis (dogs were treated with a 
cumulative dose of 12b80 of 4, 18, 20, 30 and 42 mg/kg) 
(Figure 2D–2I).
Three dogs had a full necropsy examination, 
including one dog treated with three cycles of 12b80 at 
dose 10 mg/kg, one dog treated with two cycles at 10 mg/
kg that developed grade 5 septic shock and one dog treated 
with three cycles at 6 mg/kg and three additional cycles at 
8 mg/kg. Two (2/3, 67%) dogs with metastasis identified 
on computed tomography at D57 had histopathology-
confirmed metastatic disease at necropsy. Sites of 
metastasis included lungs, thoracic vertebrae, and ischium. 
Post-mortem examination of the dog with grade 5 septic 
shock revealed a duodenal ulceration and perforation. 
No evidence of cancer cells was noted at this site and no 
evidence of distant macroscopic metastatic disease was 
Figure 1: Circulating blood cell counts in dogs treated with 12b80. The protocol included three cycles of 12b80 intravenous 
injections, administered every three weeks (D1, D22, D43). Neutrophil count of 1.500 × 109/L and platelet count of 75 × 109/L are shown 
(dotted lines). Data are represented as mean ± SD.
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observed at necropsy. No gastrointestinal ulceration was 
reported on necropsy of the two other dogs.
DISCUSSION
Spontaneous tumors in companion dogs represent a 
valuable model for human cancer biology and translational 
cancer therapeutics. The objectives of this dose escalation 
study were to evaluate the safety, tolerability and the MTD 
of intravenous 12b80 in client-owned dogs with naturally 
occurring osteosarcoma. Four doses were evaluated and 
the MTD of 12b80 in dogs was determined at 8 mg/kg, 
administered every three weeks for three cycles.
The results of this clinical trial showed that 12b80 
was well tolerated in dogs. The safety profile of 12b80 
included 31 TEAE with 94% (29/31) of grade 1 or 2 
toxicities. The most frequently reported TEAE were IHR 
and gastrointestinal disorders. At the MTD of 8 mg/kg, 
all TEAE were reversible and no severe myelotoxicity 
was reported. Immediate hypersensitivity reactions were 
reported in four dogs treated with 12b80 and included 
signs of agitation, head shaking, pruritus, acute cutaneous 
erythema, or subcutaneous edema. All signs consistent 
with IHR were grade 1 and resolved with the reduction 
of the 12b80 infusion rate and prophylactic antihistamine 
medications. Immediate hypersensitivity reactions, caused 
by histamine release, have been reported in dogs in the 
first minutes of doxorubicin infusion [28]. Clinical signs 
usually resolve with drug withdrawal, and the majority 
of dogs tolerates resumption of the drug with a slower 
infusion rate. Others common TEAE with 12b80 were 
gastrointestinal disorders including vomiting, diarrhea 
and decreased appetite. All digestive disorders were 
mild to moderate (grade ≤ 2) and resolved spontaneously 
or with symptomatic medications. Here, no treatment 
discontinuation was noted due to IHR or gastrointestinal 
adverse events.
Severe TEAE occurred in two dogs treated at dose 
10 mg/kg and were considered as DLT. One dog developed 
one grade 3 phlebitis with skin and subcutaneous 
necrosis which required a surgical intervention. Severe 
tissue ulceration and necrosis has been described with 
doxorubicin and bisphosphonate extravasation in dogs [29, 
30]. Here, no injection site events were reported during the 
12b80 administration, and no perivascular necrosis was 
observed. This dog had received the 12b80 IV through an 
Figure 2: 12b80 cardiac toxicity and antitumor activity in dogs. (A–C) Microscopic photographs of post-mortem cardiac 
histopathology from three dogs treated with 12b80 cumulative dose of 20 mg/kg (A), 30 mg/kg (B), and 42 mg/kg (C). No dose-limiting 
cardiotoxicity was noted, rare individual cell necrosis was observed in the dog treated with 42 mg/kg (C, arrowhead), diffuse increased 
cardiomyocyte cell density was noted in the dog treated with 20 mg/kg (A, *) and no histopathological abnormalities were found in the 
dog treated with 30 mg/kg (B). Original magnification ×40. Hematoxylin-Eosin staining. Bar = 50 µm. (D–I) Microscopic photographs 
of bone tumor biopsy before treatment (D–F) and post treatment (G–I) in the same three dogs treated with 12b80 cumulative dose of 20 
mg/kg (D and G), 30 mg/kg (E and H), and 42 mg/kg (F and I). After treatment, the tumor biopsy shows large necrotic areas with nucleus 
debris (G–I, arrowheads) or “ghost cells” (G, °). Original magnification ×40. Hematoxylin-Eosin staining. Bar = 50 µm. (J–M) Bone tumor 
computed tomography in two dogs treated with 12b80 cumulative dose of 24 mg/kg (J, pretreatment; K, post treatment), and 30 mg/kg (L, 
pretreatment; M, post treatment). Stable disease was noted at day 57 based on the Response Evaluation Criteria in Solid Tumors version 1.0.
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indwelling catheter changed every 24 hours and this event 
occurred 7 days after the administration. The phlebitis and 
subcutaneous necrosis were suspected to be correlated 
with catheter indwell time following 12b80 administration. 
Following surgical debridement, the dog completely 
recovered, and no further complications were documented. 
Following this event, the protocol was adjusted using a 
catheter removed after each chemotherapy administration 
and no other injection site toxicity was reported. The 
second severe TEAE included one septic shock secondary 
to septic peritonitis, in a Rottweiler treated with two cycles 
of 12b80 at 10 mg/kg. This event occurred 14 days after 
the last dose of 12b80. Post-mortem examination revealed 
a duodenal ulceration and perforation and no evidence 
of cancer cells was noted at this site on histopathological 
examination. This dog had concomitant NSAID treatment 
initiated before enrollment. Long-term NSAID is one of 
the most common cause of gastroduodenal ulcer disease 
in dogs and particularly reported in Rottweilers [31]. It 
remains unclear whether this grade 5 TEAE was directly 
associated with 12b80 administration or related to the 
combination of concomitant NSAID medications allowed 
in the trial. Of interest, no gastrointestinal ulceration was 
reported on necropsy of the two other dogs included in 
the study and treated with a cumulative dose of 12b80 
of 30 mg/kg and 42 mg/kg, respectively. These two dogs 
were also treated with long-term NSAID medications. 
Consequently, because two dogs experienced a DLT at dose 
10 mg/kg, the dose escalation was discontinued and the 
MTD of 8 mg/kg was defined as the highest tolerated dose.
As a vectorized form of doxorubicin, the results 
of this canine trial demonstrate that 12b80 expends the 
MTD of doxorubicin up to four times the standard dose of 
30 mg/m2 in dogs. Doxorubicin is a potent anthracycline 
antitumor antibiotic agent with cytotoxic effects and 
low therapeutic index. Dose dependent bone marrow 
suppression and cumulative cardiotoxicity limit its clinical 
usage in dogs [32]. In dogs, the MTD of doxorubicin has 
been determined at 30 mg/m2 associated with an increased 
risk of cardiotoxicity with cumulative doses greater than 
240 mg/m2 [33]. In this trial, the dose of 12b80 was 
escalated from 4 mg/kg to 10 mg/kg, which represents 
an equivalent calculated dose of doxorubicin ranging 
from 48 mg/m2 to 159 mg/m2 per cycle and a cumulative 
calculated dose ranging from 48 mg/m2 to 477 mg/m2. One 
dog with intra-patient dose escalation of 12b80 received 
a cumulative dose of doxorubicin of 528 mg/m2. No 
statistically significant decrease in neutrophil counts was 
noted seven days post treatment. The serum biochemical 
evaluation profiles provided supportive evidence for the 
safety of 12b80. There was only one transient grade 2 
increase in ALT and urea blood levels observed in one dog 
which spontaneously resolved before the following cycle. 
No hematological or biochemical adverse event requiring 
either dose reduction or treatment discontinuation was 
reported.
Repeated doses of doxorubicin can result in 
potentially life-threatening cardiotoxicity in dogs 
[28, 33]. Clinical findings of doxorubicin-induced 
cardiotoxicity include arrhythmias and decreased 
systolic function [34]. Histopathological findings of 
chronic irreversible cardiotoxicity include myofibrillary 
atrophy and degeneration, interstitial edema and fibrosis, 
swelling of the sarcoplasmic reticulum, and cytoplasmic 
vacuolation [32, 33]. In this trial, echocardiographic 
and electrocardiogram evaluation were repeated after 
completion of the three cycles of 12b80 in six (60%) dogs. 
No significant, sustained changes in cardiac parameters 
or cardiac function were identified in any dogs. Three 
(3/6, 50%) dogs had post-mortem cardiac histopathology 
performed. Those dogs received a cumulative dose 
of 12b80 of 20 mg/kg, 30 mg/kg and 42 mg/kg, which 
represents the equivalent calculated cumulative dose 
of doxorubicin of 264 mg/m2, 360 mg/m2 and 528 mg/
m2, respectively. No cardiac DLT was observed on 
histopathology. Rare individual cell necrosis was noted in 
the dog treated at a 42 mg/kg cumulative dose and diffuse 
increased cardiomyocytes density was reported in the dog 
treated at a 20 mg/kg cumulative dose.
The results of this trial in companion dogs provide 
strong support that the vectorization of doxorubicin with 
an HBP significantly increases the MTD of doxorubicin 
in dogs, up to four times the standard dose of 30 mg/m2 
without associated DLT. The bone targeting and local 
release of doxorubicin from the 12b80 in an acidic bone 
tumor environment is likely to have prevented excessive 
systemic interaction of the doxorubicin with normal 
proliferative cells and therefore limiting cellular damage 
due to oxidative reactions. Further pharmacokinetic 
analysis will be investigated in a phase II study comparing 
the plasma concentration of doxorubicin between 12b80 
and nonvectorized doxorubicin.
Preliminary clinical antitumor activity of 12b80 was 
appreciable in the form of stable disease without evidence 
of metastatic disease in two dogs at D57. Quality of life 
monitoring showed stable quality of life to improved 
quality of life in the majority of the dogs treated with 
12b80. Histopathology analysis of the bone tumor biopsies 
revealed a stable mitotic index in two dogs following 
three cycles of 12b80 and increased necrosis in five dogs 
on post-mortem analysis. The median survival time for 
dogs that completed the three cycles of 12b80 was 157 
days (range: 56–766). For comparison, multiple reports 
described a survival ranging from 75 to 209 days for dogs 
with appendicular osteosarcoma treated with radiation 
therapy in combination with or without chemotherapy 
[20–22, 24].
In conclusion, this pilot dose escalation study 
demonstrates both a promising safety profile and 
preliminary clinical antitumor activity of 12b80 
in a companion dog model of naturally occurring 
osteosarcoma. These results hold promise for the ongoing 
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clinical development and potential translational relevance 
of 12b80 in dog and human patients with osteosarcoma, 
particularly for non-operable or metastatic bone disease. 
This pilot study will be followed by a phase II randomized 
double-blind study to compare the safety and antitumor 
activity of 12b80 and nonvectorized doxorubicin in client-
owned dogs with naturally occurring osteosarcoma. This 
ongoing phase II study will explore pharmacokinetic/
pharmacodynamic profiles and clinical efficacy with 
translational objectives for both dogs and humans.
MATERIALS AND METHODS
Dose escalation design and treatment
The study was conducted as a prospective, open-
label, phase I dose escalation trial to assess the safety and 
tolerability, MTD and DLT of 12b80 in dogs with naturally 
occurring osteosarcoma. The study design and the data 
analysis were carried out by OCR (Oncovet-Clinical-
Research), Parc Eurasanté, Loos, France. The clinical trial 
was conducted at Oncovet, Villeneuve d’Ascq, France. 
The 12b80 was provided by Atlanthera laboratory (Saint 
Herblain, France).
An accelerated dose-titration design, including one 
or two dogs enrolled at the initial doses was used followed 
by a 3 + 3 design [35]. Dogs started 12b80 treatment at 
a dose of 4 mg/kg (n = 1) and 6 mg/kg (n = 2). No DLT 
was observed at the initial doses and additional dogs were 
enrolled to determine the MTD in a 3 + 3 dose escalation 
design. In each cohort, a minimum of 3 dogs were included 
and received the same dose during the protocol. The next 
cohorts were treated at increasing dose levels according 
to the following criteria: (i) if no DLT was observed in 
the 3 dogs treated in a cohort, another three dogs could be 
treated at the next higher dose level; (ii) if one of the three 
dogs experienced a DLT, three more dogs were treated 
at the same dose level; (iii) if at least two dogs among a 
cohort of three or six dogs experienced a DLT, the dose 
escalation was discontinued. The recommended dose was 
defined as the dose level just below the dose level where 
two dogs developed DLT.
Four doses were evaluated: 4 mg/kg (cohort 1; 
n = 1), 6 mg/kg (cohort 2; n = 2), 8 mg/kg (cohort 3; 
n = 3), 10 mg/kg (cohort 4; n = 4) (Table 2). All dogs 
involved in the trial followed the same protocol over a 
period of nine weeks. The protocol included three cycles 
of 12b80 intravenous (IV) injections, administered every 
three weeks (day 1, day 22, day 43). For the doses 4 and 
6 mg/kg, the total prescribed dose was divided in two 
administrations of 1-hour constant rate infusion over 24 
hours. Immediate hypersensitivity reactions (IHR) were 
noted at the doses 8 and 10 mg/kg, thus the protocol 
was adjusted from two to three or four intravenous 
administrations of 1-hour of each over 48 hours and 
premedication with diphenhydramine (1 mg/kg, IV) and 
ranitidine (2 mg/kg, IV) were administered 20 minutes 
before the IV administration of the 12b80. The prescribed 
dose was diluted in sterile isotonic sodium chloride 0.9% 
solution to form a final concentration of 2 mg/ml. The 
drug was administered IV through an indwelling catheter 
placed into a cephalic vein using a syringe driver. The 
indwelling catheter was changed every 24 hours. One dog 
treated at the dose level 10 mg/kg developed one grade 
3 phlebitis and necrosis at the IV injection site, thus the 
protocol was adjusted with a catheter removed after each 
chemotherapy administration. Dogs were hospitalized for 
three days during each cycle (days 1–3, days 22–24, and 
days 43–45).
12b80 (hydroxybisphosphonate linked 
doxorubicin)
The molecule 12b80 combines doxorubicin bound 
to a bone targeting HBP vector using a pH-sensitive linker 
(thiocarbohydrazide) (Figure 3). The design and synthesis 
of 12b80 are patented (WO 2016079327 A1). Each 
molecule of 12b80 contains one molecule of doxorubicin. 
The molecular weights of 12b80 and doxorubicin are 1431 
g/mol and 543 g/mol, respectively. Toxicological data in 
rodents have shown that the MTD of 12b80 was more than 
three-fold higher than doxorubicin after a single injection 
and ten-fold higher after repeated doses of nine injections 
[25]. Toxicological data were preliminary evaluated in 
four Beagle dogs. Dogs were treated intravenously once 
a week for three weeks with intra-patient dose escalation 
of 12b80 between 3 and 16 mg/kg, resulting in cumulative 
doses ranging from 15 to 30 mg/kg. No death related to 
treatment was reported. Dose-dependent hematologic 
toxicity was observed with the highest dosage. Immediate 
hypersensitivity reactions were noted when the total dose 
was administered in a single injection but IHR were 
prevented during subsequent injections when the total 
prescribed dose was divided in two administrations. No 
DLT was observed on heart, bone and brain post-mortem 
histopathology.
In our trial, the first cohort of dogs was treated 
at a starting dose of 4 mg/kg (i.e., 1.5-fold higher than 
the equivalent calculated standard dose of doxorubicin 
in dogs). This dose was considered to be safe based on 
extrapolation from toxicological data profiles in rodents 
and Beagle dogs.
Dog selection
Ten client-owned dogs presenting with naturally 
occurring osteosarcoma were enrolled in the trial. 
Dogs were considered eligible for inclusion if they 
were weighing 20–70 kg, diagnosed with untreated 
osteosarcoma, with or without evidence of macroscopic 
metastatic disease, with no evidence of significant 
biochemical abnormalities or blood cytopenia which 
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precluded the use of cytotoxic drugs or bisphosphonates, 
and whose owners had declined standard anticancer 
therapies. Dogs were excluded from the study participation 
if they had surgery, radiation therapy, or had received 
prior systemic chemotherapy or bisphosphonates. Dogs 
with underlying cardiac disease were also excluded 
from the study population. Oral analgesics excluding 
bisphosphonates were deemed acceptable for the trial 
participation.
After enrollment, dogs were excluded from the 
trial in the instance of disease progression (including 
pathological fractures confirmed on imaging), DLT, 
or withdrawal based on the decision of the owner or 
investigator. Data collection was discontinued after the 
exclusion or death of the last dog included in the study.
Ethical approval was obtained from the OCR Ethical 
Committee before trial initiation. Dog owners were 
informed prior to the trial of available treatment options, 
including surgery with adjuvant chemotherapy and 
traditional palliative therapies. Written informed consent 
was obtained from the owner before enrollment of each 
dog. Owners were permitted to withdraw their dog from 
the trial at any time.
Initial staging
At enrollment, all dogs had a complete clinical 
staging performed including a complete blood count, 
biochemistry panel, contrast-enhanced whole-body 
computed tomography, urine analysis, echocardiogram 
and electrocardiogram. Definitive diagnosis of 
osteosarcoma was confirmed based on histopathological 
assessment on tumor biopsy performed with 8-–11-gauge 
Jamshidi needles. Tumors were described as osteoblastic, 
chondroblastic, fibroblastic, and telangiectatic.
Safety analysis
Safety analysis was conducted in all dogs that 
received at least one dose of 12b80. Safety analysis 
included treatment-emergent adverse events (TEAE), 
laboratory safety assessments and quality of life 
evaluation. Laboratory safety assessments included the 
measurement of a complete blood count and a chemistry 
profile (total proteins, albumin, globulins, urea, creatinine, 
glucose, ionized calcium, sodium, potassium, chloride 
concentrations and alkaline phosphatase, and alanine 
transaminase activities). Treatment-emergent adverse 
events were assessed during each scheduled visit and 
graded according to the VCOG-CTCAE, version 1.1 [26]. 
The adverse event grade assigned to each dog was based 
on the highest grade of hematological and biological 
toxicity reported and the highest grade of gastrointestinal 
or constitutional clinical signs noted. Dose-limiting 
toxicity was defined as any of the following TEAE: any 
grade 5 toxicity, any prolonged (> 48 hours) asymptomatic 
grade 4 neutropenia or thrombocytopenia, any grade ≥ 3 
febrile neutropenia, and any grade ≥ 3 nonhematological 
toxicity.
Owners were questioned about signs of adverse 
clinical effects using a quality of life questionnaire adapted 
from Lynch and colleagues and completed at day 1 and 
day 57 [36]. A complete blood count was performed before 
and seven days after each cycle. Recovery of absolute 
neutrophils count to 1500 cells per µL and platelets count to 
75000 platelets per µL was required before starting the next 
Figure 3: Chemical structure of 12b80. The molecule 12b80 combines doxorubicin bound to a bone targeting hydroxybisphosphonate 
vector using a pH-sensitive linker. This hydroxybisphosphonate linked doxorubicin compound was designed to specifically trigger 
doxorubicin release in an acidic bone tumor microenvironment.
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cycle. For dogs with prolonged (> 48 hours) asymptomatic 
grade 4 neutropenia, febrile neutropenia, and grade 3 
gastrointestinal adverse events, the dose was reduced by 
20% for the following cycles. If the neutrophil count was 
lower than 1500 /µL or the platelet count was lower than 
75 000 /µL at the time of the next cycle, the chemotherapy 
administration was postponed for one week. If a delay of 
more than two weeks occurred, treatment was discontinued. 
Prophylactic broad-spectrum antibiotic therapy was 
administrated for dogs with grade ≥ 3 asymptomatic 
neutropenia. Dogs with febrile neutropenia, and grade ≥ 
3 gastrointestinal adverse events were hospitalized and 
treated with supportive care and IV antibiotics. During drug 
administration, dogs were evaluated for hypersensitivity 
reactions. A physical examination was performed to 
identify any sign of agitation, head shaking, pruritus, acute 
cutaneous erythema, or subcutaneous edema. The heart rate, 
respiratory rate, and body temperature were monitored, and 
blood pressure was measured every 30 minutes during 
infusion. Cardiac evaluation including an echocardiogram 
and electrocardiogram was performed prior to treatment 
initiation and was repeated after completion of the three 
cycles of 12b80 (day 57).
Assessment of response and follow-up
After completion of the three cycles (day 57), dogs 
underwent a complete end-staging including a complete 
blood count, biochemistry panel, contrast-enhanced 
whole-body computed tomography, urine analysis, 
echocardiogram and electrocardiogram. A bone tumor 
biopsy was repeated if no pathological fracture was 
identified on the computed tomography images. Response 
to treatment was defined according to the RECIST criteria 
v1.0 [27]. Follow-up contrast-enhanced whole-body 
computed tomography was performed four and six months 
after completion of treatment.
Study endpoints
The primary endpoints of the study were safety, 
tolerability, DLT and the MTD. Safety analysis evaluated 
the occurrence of TEAE graded according to the VCOG-
CTCAE v1.1 [26]. The secondary endpoints were the 
evaluation of the preliminary antitumor activity of 12b80 
in dogs with osteosarcoma including quality of life 
assessment, overall response rate and overall survival 
evaluated by RECIST criteria v1.0 [27].
Statistical analysis
Categorical variables were expressed as numbers and 
percentages. For continuous normally distributed variables, 
data were expressed as mean and standard deviation (SD), 
and groups were compared with t-test. For nonnormally 
distributed continuous variables, data were expressed 
as median and range, and groups were compared using 
Wilcoxon rank test. Overall survival (OS) was defined as 
the time between the first cycle initiation and death from 
any cause. Overall survival was used instead of disease 
specific survival since necropsy results were not available 
in all dogs to confirm osteosarcoma-related death. Results 
were considered statistically significant with a P value < 
0.05. The statistical analysis was performed using SPSS 
version 24.0 software (SPSS A, Inc., Chicago, IL, USA).
Abbreviations
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